Dysmenorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Dysmenorrhea Market Outlook

Thelansis’s “Dysmenorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dysmenorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dysmenorrhea Overview

Dysmenorrhea is a Greek term for “painful monthly bleeding”. It can be classified as primary and secondary dysmenorrhea. Primary dysmenorrhea is a lower abdominal pain during the menstrual cycle, not associated with other diseases or pathology. In contrast, secondary dysmenorrhea is usually associated with other pathology inside or outside the uterus. Dysmenorrhea is a common complaint among women during their reproductive age. It is associated with significant emotional, psychological, and functional health impacts. During menstruation, chemicals called “prostaglandins” form in the lining of the uterus. They cause muscle contractions in the uterus, which can trigger pain and decrease blood flow and oxygen to the uterus. Similar to labor pains, these contractions can cause significant pain and discomfort. Prostaglandins may also contribute to other menstrual symptoms, such as nausea and diarrhea.

Associated risk factors are:

• Age
• Smoking
• Attempts to lose weight
• Higher body mass index
• Depression/anxiety
• Earlier age at menarche
• Nulliparity
• Longer and heavier menstrual flow
• Family history of dysmenorrhea
• Disruption of social networks

The pain of dysmenorrhea is crampy and usually located in the lower abdomen; some people also have severe pain in the back or thighs. The pain usually begins just before or as menstrual bleeding begins and gradually improves over one to three days. The pain usually occurs intermittently and can range from mild to disabling. Other symptoms accompanying cramping include nausea, diarrhea, dizziness, fatigue, headache, or a flu-like feeling. The pathophysiology of primary dysmenorrhea is not well understood. Nevertheless, the identified cause is due to the hypersecretion of the prostaglandins from the uterine inner lining. Prostaglandin F2alpha (PGF-2a) and Prostaglandin PGF 2 increase the uterine tone and also causes high-amplitude contractions of the uterus. Also, vasopressin has been linked to primary dysmenorrhea. Vasopressin increases uterine contractility and can cause ischemic pain due to its vasoconstriction effects. Progesterone levels drop before menstruation, increasing PG production and triggering dysmenorrhea. Endometriosis and adenomyosis are the most common causes of secondary dysmenorrhea in premenopausal women. Secondary dysmenorrhea complication varies depending on the etiology. Complications may include infertility, pelvic organ prolapse, heavy bleeding, and anemia.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Dysmenorrhea – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034